Added to YB: 2026-02-25
Pitch date: 2026-02-22
CGEM [bullish]
Cullinan Therapeutics, Inc.
+5.08%
current return
Author Info
Clinical Catalysts breaks down the science and strategy behind pharma market movers. Sign up for the newsletter.
Company Info
Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States.
Market Cap
$806.4M
Pitch Price
$13.58
Price Target
21.80 (+56%)
Dividend
N/A
EV/EBITDA
-1.98
P/E
-3.71
EV/Sales
N/A
Sector
Biotechnology
Category
growth
The Catalyst-Stacked Biotech With Multibagger Potential ($CGEM)
CGEM: Clinical-stage biopharma with $475.5M cash (runway to 2029). Lead: zipalertinib EGFR ex20 NSCLC (35% ORR, 9-10mo PFS, NDA Q1'26, 50/50 profit w/ Taiho). CLN-049 AML bispecific (30% CRc, FDA Fast Track). CLN-978 autoimmune CD19xCD3 (RA/SLE data Q2'26). Risk-weighted fair value ~$21.80 vs $13.65 (~60% upside). Key risks: competitive field, clinical execution
Read full article (6 min)